---
schema_version: "secwatch.filing_event.v1"
accession: "0001674930-26-000028"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2026-06-01T23:07:35+00:00"
generated_at: "2026-06-02T10:15:19.061102+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026

## Summary
- FID-007 + cetuximab showed 61.9% objective response rate in PD-1 resistant R/M HNSCC.
- Median progression-free survival 6.7 months; median duration of response 7.4 months.
- One-year overall survival rate 63.4% in target population.
- Phase 3 study is planned based on these results.
- Data cutoff April 16, 2026; presentation at ASCO 2026 Rapid Oral Abstract Session.

## SEC filing metadata
- accession: 0001674930-26-000028
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2026-06-01T23:07:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/0001674930-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/flgt-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001674930-26-000028
- JSON: https://secwatch.observer/filing/0001674930-26-000028.json
- Plain text: https://secwatch.observer/filing/0001674930-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.